May. 13 at 11:58 AM
No, 4D Molecular Therapeutics
$FDMT did not file a
$400 million S-3 on Friday.Instead, the company filed an S-3 Registration Statement with the SEC on Thursday, May 7, 2026, for an aggregate amount of
$200 million.Key operational details of this specific filing include:Purpose: It functions entirely as a replacement shelf registration. It is transferring
$200 million of unsold securities from an expiring August 2023 S-3 filing (set to lapse on August 15, 2026).Dilution Impact: Because this filing simply carries forward previously registered, unsold capacity under SEC Rule 415(a)(6), it does not represent a newly added dilution event or an expansion of their existing capital-raising limits.
